Little is known about the deposition and turnover of proteoglycans in liver fibrosis, despite their abundance in the extracellular matrix. Versican plays diverse roles in modulating cell behavior in other fibroproliferative diseases, but remains poorly described in the liver. Hepatic fibrosis was induced by carbon tetrachloride treatment of C57BL/6 mice over 4 weeks followed by recovery over a 28-day period. Primary mouse hepatic stellate cells (HSCs) were activated in culture and versican was transiently knocked down in human (LX2) and mouse HSCs. Expression of versican, A Disintegrinlike and Metalloproteinase with Thrombospondin-1 motifs (ADAMTS)-1, -4, -5, -8, -9, -15, and -20, and markers of fibrogenesis were studied using immunohistochemistry, real-time quantitative PCR, and western blotting. Immunohistochemistry showed increased expression of versican in cirrhotic human livers and the mouse model of fibrosis. Carbon tetrachloride treatment led to significant increases in versican expression and the proteoglycanases ADAMTS-5, -9, -15, and -20, alongside TNF-α, α-smooth muscle actin (α-SMA), collagen-1, and TGF-β expression. During recovery, expression of many of these genes returned to control levels. However, expression of ADAMTS-5, -8, -9, and -15 showed delayed increases in expression at 28 days of recovery, which corresponded with decreases in versican V0 and V1 cleavage products (G1-DPEAAE 1401 and G1-DPEAAE 441 ). Activation of primary HSCs in vitro significantly increased versican, α-SMA, and collagen-1 expression. Transient knockdown of versican in HSCs led to decreases in markers of fibrogenesis and reduced cell proliferation, without inducing apoptosis. Versican expression increases during HSC activation and liver fibrosis, and proteolytic processing occurs during the resolution of fibrosis. Knockdown studies in vitro suggest a possible role of versican in modulating hepatic fibrogenesis.
Little is known about the deposition and turnover of proteoglycans in liver fibrosis, despite their abundance in the extracellular matrix. Versican plays diverse roles in modulating cell behavior in other fibroproliferative diseases, but remains poorly described in the liver. Hepatic fibrosis was induced by carbon tetrachloride treatment of C57BL/6 mice over 4 weeks followed by recovery over a 28-day period. Primary mouse hepatic stellate cells (HSCs) were activated in culture and versican was transiently knocked down in human (LX2) and mouse HSCs. Expression of versican, A Disintegrinlike and Metalloproteinase with Thrombospondin-1 motifs (ADAMTS)-1, -4, -5, -8, -9, -15, and -20, and markers of fibrogenesis were studied using immunohistochemistry, real-time quantitative PCR, and western blotting. Immunohistochemistry showed increased expression of versican in cirrhotic human livers and the mouse model of fibrosis. Carbon tetrachloride treatment led to significant increases in versican expression and the proteoglycanases ADAMTS-5, -9, -15, and -20, alongside TNF-α, α-smooth muscle actin (α-SMA), collagen-1, and TGF-β expression. During recovery, expression of many of these genes returned to control levels. However, expression of ADAMTS-5, -8, -9, and -15 showed delayed increases in expression at 28 days of recovery, which corresponded with decreases in versican V0 and V1 cleavage products (G1-DPEAAE 1401 and G1-DPEAAE 441 ). Activation of primary HSCs in vitro significantly increased versican, α-SMA, and collagen-1 expression. Transient knockdown of versican in HSCs led to decreases in markers of fibrogenesis and reduced cell proliferation, without inducing apoptosis. Versican expression increases during HSC activation and liver fibrosis, and proteolytic processing occurs during the resolution of fibrosis. Knockdown studies in vitro suggest a possible role of versican in modulating hepatic fibrogenesis. Chronic liver disease remains a major public health problem worldwide [1] [2] [3] [4] [5] and is complicated by progressive fibrosis and cirrhosis. Chronic liver injury, irrespective of etiology, is typically characterized by inflammation and increased deposition of extracellular matrix (ECM) with a greater proportion of fibrillar collagens. This fibrotic ECM leads to adverse functional alterations in the liver, including portal hypertension and liver failure secondary to hepatocellular dysfunction. [6] [7] [8] [9] [10] The accumulation of fibrotic tissue results mainly from sustained activation of hepatic stellate cells (HSCs) to a fibroblastic phenotype, in response to many factors, including stimulation by proinflammatory and fibrogenic cytokines (particularly TGF-β), tissue hypoxia, reactive oxygen species, innate immune responses via interaction with Toll-like receptors (TLRs), the stiffness of the ECM, and ECM/fibroblast interactions. 5, [11] [12] [13] [14] [15] [16] [17] During the fibroproliferative stage, treatment of the underlying cause of liver disease results in the best prognostic outcome with disease reversal occurring in many patients. [18] [19] [20] [21] Matrix metalloproteinase (MMP)-mediated degradation of fibrillar collagens is a well-established aspect of recovery from liver fibrosis in both experimental models and human disease, with a majority of the MMPs being synthesized by HSCs. 7, [22] [23] [24] The tissue inhibitor of metalloproteinase (TIMP) family of endogenous inhibitors is involved in regulating the activity of MMPs and collectively, MMP and TIMP activity contribute to regulation of HSC activity during fibrogenesis and recovery. [25] [26] [27] [28] [29] While the changes in collagen type I and III turnover have been well described in liver fibrosis, less is known about changes in proteoglycans that are the most abundant component of the ECM.
Proteoglycans are a diverse group of highly glycosylated proteins composed of a core protein covalently linked to a variable number of negatively charged, sulfated glycosaminoglycan side chains. Proteoglycans have numerous biological functions in the ECM including modulating cell/tissue homeostasis, cell adhesion/migration, as well as regulation of cellular signaling. 30 Early work has established that heparan sulfate proteoglycans are more abundant than chondroitin sulfate proteoglycans (CSPGs) in the normal liver and play important roles in maintaining hepatocyte phenotype. [31] [32] [33] However, under remodeling conditions, CSPGs are increased much more significantly, which could reflect a modulatory role. 31, 32 The small leucine-rich proteoglycans decorin, biglycan, and lumican have all been associated with hepatic fibrosis. 34, 35 Early studies identified the large CSPG versican in the liver and suggested that expression increases with fibrosis. [36] [37] [38] Versican is overexpressed in patients with non-alcoholic steatohepatitis, compared with obese control patients 39 and we have recently described versican upregulation in HSCs activated in culture. 40 Much remains to be elucidated about the roles of specific CSPGs in the liver.
Versican is a large, alternatively spliced, aggregating CSPG with a molecular weight that can be 41000 kDa and a ubiquitous pattern of expression. 36, 41 It is essential in development, wherein versican null mice die during embryogenesis. 42 Conditional knockout of versican has demonstrated its importance both during chondrogenesis and in binding the profibrotic cytokine TGF-β. 43 Versican is a major component of the early fibroproliferative matrix in lung fibrosis where its deposition is associated with fibroblast migration and proliferation, preceding collagen deposition. [44] [45] [46] It is also associated with the neointima in atherosclerosis and restenosis. 47 Versican is present in the stroma of many different forms of cancer, including liver cancer, where its expression appears to correlate reliably with growth, invasion, and metastatic potential. [48] [49] [50] Versican has been shown to play modulatory roles in cell proliferation, differentiation, adhesion, and the homeostatic integrity of the ECM. 48, 51 It is a central component of inflammatory processes and is involved in multiple protein-binding interactions and modulation of leukocytes and lympohocytes. 52, 53 Versican has also been shown to activate macrophages through toll-like receptor 2 (TLR2) and its co-receptors, TLR6 and CD14, leading to the production of the proinflammatory cytokine TNF-α, in addition to macrophage activation. 54 Proteolytic processing of versican occurs by several different members of the ADAMTS (A Disintegrin-like and Metalloproteinase with Thrombospondin-1 motifs) family of enzymes. ADAMTS-1, -4, -5, -9, -15, and -20 have all been demonstrated to cleave versican [55] [56] [57] [58] and by homology, ADAMTS-8 is presumed to also. This cluster of ADAMTS enzymes represents slightly less than half of the ADAMTS family and is considered the proteoglycan cleaving 'super-clade'. 59 ADAMTS processing of versican produces several cleavage sites, 55, 60, 61 the best known of these is the DPEAAE↓ARRGQ site. 55 Cleavage at this site releases the N-terminal globular domain of versican (the G1 domain) and a portion of the GAG-β domain, leading to a 441 amino acid N-terminal fragment of the V1 isoform (human or mouse) with several potential glycosylation sites. 41, 62 In the larger versican V0 isoform, the GAG-α domain is also included in this cleaved portion leading to a 1428 residue N-terminal fragment in human versican or 1401 in mouse, that is predicted to contain 5-8 glycosaminoglycan side chains, in addition to several N-and O-linked glycosylations. 36, 62 Neo-epitope antibodies to the C-terminal DPEAAE sequence have permitted investigation of this G1-DPEAAE cleavage product in tissue remodeling processes. Proteolytic processing of versican is essential in a number of developmental processes and generates bioactive fragments including G1-DPEAAE 441 . [63] [64] [65] [66] [67] [68] It is becoming increasingly clear that the regulated expression and proteolytic processing of versican are critically involved in influencing cell phenotype during inflammation and remodeling. 51, 69 Bioactive ECM proteolytic fragments are increasingly recognized to regulate cellular function and have been generally referred to as matrikines. 70 Recently, the G1-DPEAAE 441 neo-epitope cleavage product of versican V1 has been dubbed 'versikine' to underscore the importance of versican cleavage in general and this versican cleavage product, in particular, in regulating tissue remodeling. 71 Given the known roles of versican in other tissues and the increases in CSPGs in liver remodeling, we hypothesized that versican expression would also play a role in the pathogenesis of hepatic fibrosis.
Here, we report that versican is dysregulated during liver fibrosis and reduces during recovery from liver injury. Furthermore, gene interference studies suggest that a decrease in versican expression is associated with deactivation of HSCs and a concomitant reduction of collagen expression, which would lead to a reduction of synthesis and deposition of fibrotic ECM.
MATERIALS AND METHODS Human Tissue Sample Collection
Human tissues were obtained through the BC Gastrointestinal Biobank from surplus materials obtained at the time of hepatectomy. Clinical samples of non-cirrhotic liver were from patients with metastatic colorectal carcinoma (n = 4) or metastatic breast carcinoma (n = 1), from patients aged 31 to 83. Clinical samples of cirrhotic liver were from patients with autoimmune hepatitis (n = 2), steatohepatitis (n = 1), primary sclerosing cholangitis (n = 1), and hepatocellular carcinoma (n = 1), from patients aged 27 to 63.
Induction of Liver Fibrosis in Mice with Carbon Tetrachloride Treatment
Three-week-old male and female C57BL/6 mice purchased from Charles River Laboratories (Senneville, QC, Canada) were housed in a temperature-humidity-controlled environment with 12 h light-dark cycles and had unrestricted access to food and water. Liver fibrosis was induced by intraperitoneal injection (i.p.) of 0.9 ml/kg carbon tetrachloride (CCl 4 ) dissolved in olive oil (1:1) twice weekly for 4 weeks. Mice treated with i.p. olive oil vehicle over 8 weeks served as controls. Following CCl 4 treatment mice were killed or allowed to recover over 3, 7, or 28 days and then killed to assess the extent of liver fibrosis and recovery. 26 There were 10 mice in each treatment and the control group although some attrition meant that statistical analysis was undertaken on the results from 9 to 10 animals per group. Maximum fibrosis was considered to be 3 days after last instillation of CCl 4 as previously described, 26 and recovery times were measured from that point. A portion of excised liver was fixed in 10% phosphate-buffered formalin for histological analysis. The remaining portions of the liver were collected in RNase-free tubes and snap-frozen in liquid nitrogen for further analysis as subsequently described.
Ethics Statement
Human tissues were obtained through the BC Gastrointestinal Biobank at Vancouver General Hospital (UBC REB # H12-03476). Patients gave consent to research use with surplus materials prior to hepatectomies being performed. Clinical data were anonymized for further research purposes. Animal work performed in this study was approved by the Animal Care and Use Committee of the University Northern British Columbia and conformed to institutional guidelines for animal experimentation (protocol: A2010.0318.006). Terminal surgeries were performed under deep anesthesia with isoflurane and all efforts were made to minimize suffering.
Histological Assessment
Immunohistochemical staining for versican was performed in all cases included in this study on 4-μm-thick paraffin sections of whole-tissue sections on the semi-automated Ventana Discovery XT instrument (Ventana Medical Systems, Tucson, AZ, USA). Antigen retrieval was standard CC1: versican rabbit polyclonal (clone HPA004726; Sigma, Abbreviations: Acta2/ACTA2, α-smooth muscle actin; Actb, actin beta; Rn18s, 18S ribosomal RNA; ADAMTS, a disintegrin-like and metalloproteinase with thrombospondin-1 motifs; Col1a1/COL1A1, collagen type I, alpha 1; Gapdhs, glyceraldehyde-3-phosphate dehydrogenase, spermatogenic; NIFK, nucleolar protein interacting with the FHA domain of MKI67; Tgfb1/TGFB1, transforming growth factor beta 1; Timp, tissue inhibitor of metalloproteinase; Tnf, tumor necrosis factor; RNA18S5, RNA 18S ribosomal 5; Vcan/VCAN, versican.
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St Louis, MO, USA) or versican mouse monoclonal (clone 12C5; Developmental Studies Hybridoma Bank, University of Iowa) 72 was applied at 1:100, followed by incubation with prediluted UltraMap anti-mouse or anti-rabbit HRP secondary, and detection with Ventana UltraMap DAB kit (Ventana). Quantitation was performed on each image with the investigator blinded to group assignment (n = 5 samples per condition). Pathological fibrosis staging was performed RNA Extraction and Real-Time Quantitative PCR Total RNA from cells or tissue samples was extracted using the RNeasy kit (Qiagen) according to the manufacturer's protocol. Quantitation and estimation of RNA purity was carried out using the NanoDrop (Thermo Scientific) spectrophotometer readings at 260 and 280 nm. Reverse transcription of 1 μg RNA was conducted for 30 min at 42°C using iScript (Bio-Rad). Quantification of target gene mRNAs was undertaken using the SYBR Green method with the Bio-Rad CFX96 real-time System (Bio-Rad). Fifteen microliters of reaction volume was used for the real-time PCR assay that consisted of 2 × (7.5 μl) Brilliant SYBR Green QPCR Master Mix (Bio-Rad), 2.5 μM of primers (2.5 μl each from the stock), and 5 μl of template. The thermal conditions consisted of an initial denaturation at 95°C for 10 min followed by 40 cycles of denaturation at 95°C for 15 s, annealing at 60°C for 30 s, and extension at 72°C for 1 min. A melting curve analysis was carried out between 50 and 95°C with a plate read every 0.1°C after holding the temperature for 5 s. The data were analyzed using Bio-Rad Manager version 2.0, and the results were exported to Microsoft Excel for further analysis. Three endogenous control genes were analyzed for stability in the CCl 4 model (Supplementary Information) and 18 s RNA was chosen as a reliable endogenous control gene. Data normalization relative to the 18 s RNA subunit was calculated using the comparative Ct (ΔΔCt) method to calculate the fold change between the control and experimental groups as previously described. 77 Primer pairs used for the different mouse and human genes are listed in Table 1 .
siRNA Constructs and Cell Transfections
The following expression plasmids were used: human versican siRNA (Santa Cruz cat. # sc-41903) and control siRNA (Santa Cruz cat. # sc-37007). Cells were transfected with specific siRNA as indicated using FugeneHD (Roche cat. # 04709713001) according to the manufacturer′s specification. 55 and cleaved poly(ADP-ribose) polymerase antibody (Cell Signaling cat. # 9544). The Protein Molecular Weight Calculator tool (http://www.sciencegateway.org/tools/pro teinmw.htm) was used to calculate versican core protein fragment sizes based on known amino acid composition.
Lactate Dehydrogenase (LDH) Assay
The LDH toxicity assay kit (Abcam Cat. # ab65393) was used according to the manufacturer's specification as recently described. 78 Briefly, released LDH in culture supernatants of LX2 cells was measured after versican siRNA knockdown. Staurosporine (Cell Signaling cat. #9953) treatment (10 nM) for 12 h was used to initiate apoptosis as a positive control for poly(ADP-ribose) polymerase cleavage. The percentage of cytotoxicity was measured by subtracting LDH content in remaining viable cells from total LDH in untreated controls. The final absorbance was measured at 490 nm. All experiments were performed in triplicate with an equal number of cells (5 × 10 6 cells/2 ml cell culture medium).
Statistical Analysis
All data are expressed as the mean ± standard error of the mean (s.e.m.). Data were evaluated using two-way (Figure 1 ) or one-way analysis of variance with Fisher's least significant difference test for multiple comparisons. A value of Po0.05 was considered to be statistically significant. Statistical analyses were performed using the GraphPad Prism software program (version 6.0f).
RESULTS

Versican is Upregulated in Liver Fibrosis and Cirrhosis
Given the consistent association of versican with many fibroproliferative disorders, we sought to investigate its role in liver fibrosis. We stained normal and cirrhotic human livers for versican and compared these with fibrotic mouse livers after 4 weeks of CCl 4 administration. Human and mouse livers both stained faintly in the absence of fibrosis, 
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with a variable staining pattern including both apparent perisinusoidal and hepatocyte cytoplasmic localization. With fibrosis and cirrhosis, both human and mouse livers stained strongly for versican ( Figure 1a ). This staining was partially subendothelial (perisinusoidal) and stromal, but substantial staining was also cytoplasmic in hepatocytes, particularly in human cirrhotic specimens. Mouse liver stained more ubiquitously for versican under conditions of laboratory induced fibrosis. Quantitation of versican staining confirmed significantly increased versican deposition in both human cirrhosis and the mouse model of liver fibrosis (Figure 1b) . To further investigate the putative role of versican in liver fibrogenesis and recovery, we employed a model of reversible liver fibrosis induced by CCl 4 . 26 Histological analysis confirmed the presence of necrosis and inflammation with thick fibrous septae after 4 weeks of injury (Figure 2a) . In those animals in whom CCl 4 administration was stopped at 4 weeks, there was resolution of inflammation and fibrosis over the following 4 weeks which was statistically significant at 3, 7, and 28 days (Figures 2a and b) . Quantitation of picrosirius red collagen staining indicated that collagen deposition was more sustained and resolution was not as rapid as morphological recovery from injury (Figure 2b ). After 4 weeks of CCl 4 -induced injury, liver fibrosis was associated with a significant increase of whole-liver versican mRNA expression (Figure 3a) . This was concomitant with an increase in collagen-1, a well described fibrosis gene. The inflammatory response was confirmed by a significant increase in liver TNF-α and fibrogenesis was confirmed by increases in TGF-β and α-SMA mRNA expression (Figure 3b ). During recovery from liver injury, the increase in versican expression decreased to basal levels by day 3 of recovery alongside collagen-1 (Figure 3a) . TNF-α, α-SMA, and TGF-β mRNA decreased to comparable levels with control mice by 3 days after cessation of CCl 4 ( Figure 3b ). Compared with α-SMA mRNA expression, there was a more gradual decrease of α-SMA protein during recovery (Figure 4a ).
Versican Expression and Processing is Dysregulated During Hepatic Fibrosis in Mice
Given the importance of versican turnover in modulation of cellular functions and fibrosis in other tissues, 51, 69 we next investigated whether versican was being proteolytically processed, using a neo-epitope antibody to the well-documented DPEAAE↓ARRGQ cleavage site (anti-DPEAAE), present in 
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TN Bukong et al both the V0 and V1 versican isoforms. 55 We identified that the V0 cleavage product, G1-DPEAAE 1401 , significantly increased at 4 weeks of CCl 4 , followed by significant decreases during recovery, though it remained elevated compared with control at 3 days of recovery (Figure 4b) . Conversely, the V1 cleavage product, G1-DPEAAE 441 or versikine, showed no significant changes during the induction of fibrosis but a significant decrease at 28 days of recovery (Figure 4c) . The V0 and V1 cleavage products were both decreased significantly below control levels at 28 days of recovery (Figures 4b and c) .
ADAMTS Proteoglycanases are Dysregulated in Liver Fibrosis
To further investigate putative mechanisms of versican turnover, we next analyzed expression of the ADAMTS proteoglycanses. We found that CCl 4 treatment over 4 weeks led to significant increases in liver ADAMTS-5, -9, -15, and -20 mRNA expression and nonsignificant increases in ADAMTS-1, -4, and -8 (Figures 5a-g ). During recovery from liver injury, ADAMTS proteoglycanases exhibited different patterns of regulation. ADAMTS-4, -15, and -20 decreased rapidly during recovery and at 28 days, ADAMTS -4 and -20 remained decreased compared with 4 weeks of CCl 4 treatment (Figures 5b, f and g ). In contrast, ADAMTS-8 was increased compared with 4 weeks of CCl 4 treatment at 28 days of recovery and ADAMTS-5, -8, -9, and -15 were all increased compared with control at 28 days of recovery (Figures 5c-f) .
Versican Expression Increases in Activated Primary
Mouse Stellate Cells Given that versican was increased significantly during hepatic fibrosis and was reduced during recovery from hepatic injury, we investigated versican expression in HSC activation as they are the main source of ECM in liver injury. Primary HSCs were isolated from 3-week-old C57BL/6 mice followed by activation during tissue culture on plastic. During stellate cell activation, versican expression increased significantly at day 5 compared with day 1 control mouse HSCs (Figure 6a) , and appeared to stay elevated through to day 21. Similarly, α-SMA and collagen-1 expression increased significantly at day 5 and appeared to stay elevated through to day 21 (Figures 6b and c) . Throughout the timecourse of HSC activation, ADAMTS-1 expression changed little with a small Versican in liver fibrosis TN Bukong et al but significant change at day 14, but ADAMTS-4 expression was significantly downregulated at all time points (Figure 6d) . Conversely, TIMP-1 showed significantly elevated expression at day 14 and TIMP-3 was significantly upregulated at days 7 and 21 ( Figure 6d ) with nonsignificant increased expression of both genes at all other time points. A reduction in ADAMTS-4 along with increased expression of TIMP-1 and -3 should contribute to a net reduction in proteoglycan turnover and a net synthetic environment. Collectively, these data are consistent with the synthesis and deposition of versican and other components of the ECM by activated HSCs.
Transient Knockdown of Versican in HSCs Leads to a Decrease in Profibrotic Gene Expression with no Effect on Cell Viability
To further characterize the role of versican in liver fibrosis, versican was transiently knocked down in an activated human HSC line (LX2 cells) 79 and in mouse primary HSCs. Versican knockdown in LX2 cells was confirmed by decreased expression of versican mRNA (Supplementary Information). Versican knockdown was associated with a nonsignificant decrease in expression of collagen-1 (Figure 7a) , and significant decreases in α-SMA (Figure 7b ), KI67 (Figure 7c) , and TGF-β1 (Figure 7d ). Versican knockdown led to a reduction in G1-DPEAAE 441 (Figure 7e) . In contrast to the in vivo model, the versican V0 cleavage product (G1-DPEAAE 1428 ) was not detected (n = 3). Transient knockdown of versican did not stimulate apoptosis as detected by poly(ADP-ribose) polymerase (Figure 7f ) or caspase-3 antibody (data not shown) and had no effect on LX2 cell viability (Supplementary Information).
Versican knockdown was also performed with primary mouse HSCs. Similar to LX2 cells, versican knockdown was associated with decreases in the fibrosis-associated genes collagen-1 and TGF-β1 (Figure 7g) . Conversely, α-SMA expression was not decreased in response to transient versican knockdown in these primary cells (Figure 7g ). Collectively these data suggest that versican knockdown inhibits features of fibrogenesis of HSCs cultured on plastic but does not induce apoptosis (in LX2 cells) and does not inhibit activation in primary HSCs (assessed by α-SMA expression) under these conditions. These findings are in concert with the hypothesis that versican may modulate HSC cell activation and functions in liver fibrosis.
DISCUSSION
The pathogenesis of liver fibrosis is closely associated with sustained hepatic inflammation which is evident in human 
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TN Bukong et al disease as well as in experimental liver models. 10 Many mechanisms leading to liver fibrosis, particularly HSC activation and collagen turnover, have been described. In this report, we present data which suggest for the first time that versican, a large ECM CSPG, is involved in the pathophysiology of hepatic fibrosis and may modulate HSC activation. We found versican to be dysregulated with significantly increased expression in human cirrhosis and in CCl 4 -induced fibrosis in mice. Versican upregulation was concomitant with increased expression and dysregulation of the proteoglycanases ADAMTS-1, -4, -5, -8, -9, -15, and -20 after 4 weeks of CCl 4 -induced injury and fibrosis in mice. Following cessation of CCl 4 and recovery from injury there was a rapid reduction of versican expression, along with variable changes in ADAMTS expression. Interestingly, a number of the ADAMTS enzymes appeared to increase again at 28 days of recovery, potentially indicating a separate phase of remodeling after the initial recovery period. For ADAMTS-8, this increase was significant compared with both control and 4 weeks of treatment. ADAMTS-8 is associated with inflammatory remodeling in the vasculature 80 and displays tumor suppressor activity, 81 but its role in liver remodeling has not been described.
During recovery from CCl 4 , there was a rapid reduction of the profibrotic genes α-SMA, TGF-β, and collagen-1 concomitant with the reduction of versican expression. Whereas the proinflammatory cytokine TNF-α decreased rapidly, ADAMTS-1, an enzyme known to be associated with inflammation and versican processing, 82 changed minimally. To study versican turnover during the gradual decrease in hepatic inflammation and reversal of fibrosis, we assessed the appearance of versican cleavage products, G1-DPEAAE 441 (recently dubbed versikine 71 ) and G1-DPEAAE 1401 , which are generated by the ADAMTS proteoglycanases. We found that the versican V0 fragment was differentially produced during injury and recovery, but the more commonly described V1 fragment (versikine), changed little, with a significant decrease seen only at the 28 days of recovery time point. In this model, it appears that processing of V0 occurs during injury and gradually decreases over 28 days of recovery, to a level less than control. Given the described roles of versican in inflammation, [52] [53] [54] the prolonged proteolytic turnover of versican is consistent with a period of sustained inflammation during resolution of fibrosis. Additionally, given that engagement of TLR2 by versican appears to be directly involved in the activation and the induction of inflammatory cytokine secretion, 83 our observation that hepatic fibrosis leads to a significant increase in versican fragments may indicate that versican processing contributes to the inflammatory response.
The prolonged proteolytic turnover of versican is associated with sustained expression of a number of the proteoglycan-degrading ADAMTS enzymes, most increasing during injury and several (ADAMTS-5, -8, -9, and -15) increasing a second time at the later recovery time point of 28 days. This second increase in proteoglycanases corresponds with the later decreases in levels of versican cleavage products below control levels. The physiological significance of these changes is not yet clear. However, we also found that there was a difference between the morphological recovery from CCl 4 and the loss of collagen staining, the latter being a more prolonged process. α-SMA protein was also not lost as rapidly as gene expression was downregulated. Thus it is possible that protein changes in the ECM endure beyond morphological recovery and might predispose to future injury. It is currently unclear if the proteolytic fragments of versican are bioactive in this model as has been shown in other tissues, but they may play a role in late remodeling of the ECM during resolution or maintenance of hepatic fibrosis. Collectively, these data shed further light on the mechanisms of ECM remodeling and their importance during the resolution of hepatic fibrosis.
In our experiments we consistently found versican G1-DPEAAE 441 or versikine, to run at an apparent molecular weight of~80 kDa. In previous literature this fragment has been referred to as a 70 kDa fragment. Based on core protein primary sequence, masses for the human and mouse G1-DPEAAE 441 V1 fragments are calculated to be 48.95 and 49.06 kDa, respectively. For the larger V0 fragments previously reported as an~220 kDa fragment, human G1-DPEAAE 1428 is calculated to be 156.73 kDa and mouse G1-DPEAAE 1401 is calculated to be 153.26 kDa. The differences in mobility may be due to the presence of N-and O-linked glycosylations, or variations in its electrophoretic mobility due to the extremely acidic pI of the core protein. 36, 41 To further characterize the role of versican in hepatic fibrogenesis, we isolated and activated primary mouse HSCs by plastic adherence. We found that following primary HSC activation, there was a significant upregulation of versican alongside other genes, α-SMA and collagen-1, known to be upregulated in hepatic fibrosis. The expression of the versican cleaving ADAMTS-4 enzyme was significantly downregulated during activation on plastic and TIMP-1 and -3 were significantly upregulated, indicating a net synthetic environment. Out of the family of four TIMPs, TIMP-3 is known to specifically inhibit the ADAMTS enzymes 84, 85 and has previously been associated with TNF activity, sustained liver inflammation, and impaired liver regeneration. 86 Our data support roles for TIMP-1 and -3 in inhibiting ADAMTS and MMP proteases during HSC activation (already established for MMPs), fibrogenesis, and stimulation of inflammation.
To assess the impact of therapeutically targeting versican in the treatment of hepatic fibrosis, we transiently knocked down versican in an activated human HSC line (LX2 cells) and primary mouse HSCs. Transient knockdown of versican in LX2 cells was associated with a significant decrease in versican mRNA and versikine fragments with no significant effect on cell viability. Additionally, transient knockdown of versican was associated with a decrease in proliferation of activated cells and markers of activation: collagen-1, α-SMA, KI67, and TGF-β. In primary mouse HSCs, transient knockdown of versican had similar effects on cell activation; however, it did not reduce α-SMA expression. It may be that the efficiency and/or duration of transient knockdown was insufficient to induce inhibition of phenotypic changes in the activating primary HSCs, whereas in the already activated HSC line, transient knockdown of versican was sufficient to inhibit markers of activation as well as markers of fibrogenesis. These observations indicate that versican has bioactivity in HSCs and loss of versican inhibits expression of fibrogenic genes and may inhibit HSC activation.
In summary, we present data indicating that during liver fibrosis, versican increases significantly and may be important in modulating HSC activation, hepatic inflammation, and fibrosis. Taken together, our findings highlight versican expression and processing as new dimensions in our understanding of the processes of hepatic inflammation and fibrosis. Future work will need to investigate whether this proteoglycan is similarly implicated in other models of chronic liver injury such as alcohol and diet-induced liver fibrosis. Therapeutic interventions aimed at modulating versican expression or turnover could be useful in ameliorating liver fibrosis. The development of future antifibrotic treatments for liver disease needs to take into account the role and proteolytic turnover of versican and other proteoglycans. A deeper understanding of the expression and turnover of versican and other proteoglycans may also lead to the development of new non-invasive markers of liver fibrosis.
Supplementary Information accompanies the paper on the Laboratory Investigation website (http://www.laboratoryinvestigation.org)
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